Quality of Life in Acromegaly and Growth Hormone Deficiency

Webb, Susan M.; Resmini, Eugenia; Santos, Alicia; Badı́a, Xavier

doi:10.1007/978-1-60761-317-6_12

Cited by 15 publications

(21 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AcroQoL scores can be analysed globally (22 questions with a 5-point Likert scale for each item), or separating physical (8 items) and psychological domains (14 items, subdivided into appearance and personal relations sub-domains, with 7 items each). Comparable results are reported in all available languages (32)…”

Section: Acromegalysupporting

confidence: 65%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Background: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases. Objective: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases. Design: Critical review of the pertinent literature and pragmatic discussion of available information. Methods: Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis. Results: QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing's disease (similar to other causes of Cushing's syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine 'cure', scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated. Conclusions: To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.

show abstract

Section: Acromegalysupporting

confidence: 65%

“…In contrast, the least impacted area is the personal relations sub-domain of the psychological dimension (32). Successful therapy is usually followed by improvement in the AcroQoL score, but disease control may not normalize QoL scores completely, as evidenced with generic questionnaires with normative data.…”

Section: Acromegalymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Assessment of quality of life In a subset of 70 HIVinfected patients and 49 control women, we evaluated quality of life by the two validated questionnaires for GHD in adults: the Questions on Life Satisfaction Hypopituitarism (QLS-H) and Adult GH Deficiency Assessment (AGHDA) (28). The scores were calculated according to standard instructions (28).…”

Section: Normal Range Hiv-infected Patientsmentioning

confidence: 99%

GH response to GHRH plus arginine is impaired in lipoatrophic women with human immunodeficiency virus compared with controls

Zirilli

Orlando

Carli

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: GH secretion is impaired in lipodystrophic human immunodeficiency virus (HIV) patients and inversely related to lipodystrophy-related fat redistribution in men. Less is known about the underlying mechanisms involved in reduced GH secretion in HIV-infected women. Design: A case-control, cross-sectional study comparing GH/IGF1 status, body composition, and metabolic parameters in 92 nonobese women with HIV-related lipodystrophy and 63 healthy controls matched for age, ethnicity, sex, and body mass index (BMI). Methods: GH, IGF1, IGF binding protein 3 (IGFBP3), GH after GHRH plus arginine (GHRHCArg), several metabolic variables, and body composition were evaluated. Results: GH response to GHRHCArg was lower in HIV-infected females than in controls. Using a cutoff of peak GH %7.5 mg/l, 20.6% of HIV-infected females demonstrated reduced peak GH response after GHRHCArg. In contrast, none of the control subjects demonstrated a peak GH response %7.5 mg/l. Bone mineral density (BMD), quality of life, IGF1, and IGFBP3 were lowest in the HIV-infected females with a GH peak %7.5 mg/l. BMI was the main predictive factor of GH peak in stepwise multiregression analysis followed by age, with a less significant effect of visceral fat in the HIV-infected females. Conclusions: This study establishes that i) GH response to GHRHCArg is lower in lipoatrophic HIVinfected women than in healthy matched controls, ii) BMI more than visceral adipose tissue or trunk fat influences GH peak in this population, and iii) HIV-infected women with a GH peak below or equal to 7.5 mg/l demonstrate reduced IGF1, IGFBP3, BMD, and quality of life.

show abstract

“…According to Webb and Badia, it is the patient who is the expert and judge in this area, because it is his/her feelings, thoughts and everyday activities that are taken into consideration. Individuals' goals, expectations, living standards and the social and cultural context of their life play a key role in their quality of life [26]. In the literature, a relationship between acromegaly and a sense of a decreased quality of life is emphasized [26][27][28][29][30][31][32][33][34][35], primarily linked to locomotor system dysfunction [36].…”

Section: Acromegaly and The Quality Of Lifementioning

confidence: 99%

“…In 1999, Webb and Badia developed a questionnaire to examine the perception of quality of life in acromegaly (AcroQoL) [26]. Their research emphasizes that the quality of life is correlated with variables such as age, the duration of the disease, radiotherapy, the presence of other symptoms, disease activity and gender, as women seemingly report a lower quality of life [26].…”

Section: Acromegaly and The Quality Of Lifementioning

confidence: 99%

The Quality of Life and Psychological, Social and Cognitive Functioning of Patients with Acromegaly

Szczęśniak¹,

Jawiarczyk-Przybyłowska²,

Rymaszewska³

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Acromegaly is a rare and chronic disease, most often caused by a pituitary adenoma. Excessive secretion of the growth hormone (GH) leads to hepatic secretion of insulin-like growth factor-1 (IGF-1), which in turn causes characteristic changes in the patient's appearance, many skeletal deformities and metabolic disorders. In addition to somatic symptoms, acromegalic patients demonstrate psychosocial and personality deficits, as well as common co-occurrence of mental disorders. There are few studies investigating acromegaly in Poland. In recent years, the concept of quality of life has become fundamental to understanding health problems. Studies dealing with acromegaly likewise tend to include assessments of quality of life of patients suffering from this endocrinopathy (Adv Clin Exp Med 2015, 24, 1, 167-172).

show abstract

Quality of Life in Acromegaly and Growth Hormone Deficiency

Cited by 15 publications

References 57 publications

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

GH response to GHRH plus arginine is impaired in lipoatrophic women with human immunodeficiency virus compared with controls

The Quality of Life and Psychological, Social and Cognitive Functioning of Patients with Acromegaly

Contact Info

Product

Resources

About